The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys
- PMID: 19378696
- PMCID: PMC3039289
- DOI: 10.1017/s1121189x00001421
The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys
Abstract
Aims: The paper reviews recent findings from the WHO World Mental Health (WMH) surveys on the global burden of mental disorders.
Methods: The WMH surveys are representative community surveys in 28 countries throughout the world aimed at providing information to mental health policy makers about the prevalence, distribution, burden, and unmet need for treatment of common mental disorders.
Results: The first 17 WMH surveys show that mental disorders are commonly occurring in all participating countries. The inter-quartile range (IQR: 25th-75th percentiles) of lifetime DSM-IV disorder prevalence estimates (combining anxiety, mood, externalizing, and substance use disorders) is 18.1-36.1%. The IQR of 12-month prevalence estimates is 9.8-19.1%. Prevalence estimates of 12-month Serious Mental Illness (SMI) are 4-6.8% in half the countries, 2.3-3.6% in one-fourth, and 0.8-1.9% in one-fourth. Many mental disorders begin in childhood-adolescence and have significant adverse effects on subsequent role transitions in the WMH data. Adult mental disorders are found to be associated with such high role impairment in the WMH data that available clinical interventions could have positive cost-effectiveness ratios.
Conclusions: Mental disorders are commonly occurring and often seriously impairing in many countries throughout the world. Expansion of treatment could be cost-effective from both employer and societal perspectives.
Conflict of interest statement
Declaration of Interest: Professor Kessler has been a consultant for GlaxoSmithKline Inc., Pfizer Inc., Wyeth-Ayerst, Sanofi-Aventis, Kaiser Permanente, and Shire Pharmaceuticals; has served on advisory boards for Eli Lilly & Company and Wyeth-Ayerst; and has had research support for his epidemiological studies from Eli Lilly and Company, Pfizer Inc., Ortho-McNeil Pharmaceuticals Inc., and Bristol-Myers Squibb.
References
-
- Berto P, D’Ilario D, Ruffo P, Di Virgilio R, Rizzo F. Depression: cost-of-illness studies in the international literature, a review. Journal of Mental Health Policy and Economics. 2000;3:3–10. - PubMed
-
- Brown TA, Barlow DH. Dimensional versus categorical classification of mental disorders in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders and beyond: comment on the special section. Journal of Abnormal Psychology. 2005;114:551–556. - PubMed
-
- Chang SM, Hahm BJ, Lee JY, Shin MS, Jeon HJ, Hong JP, Lee HB, Lee DW, Cho MJ. Cross-national difference in the prevalence of depression caused by the diagnostic threshold. Journal of Affective Disorders. 2008;106:159–167. - PubMed
-
- Connor KM, Davidson JR. SPRINT: a brief global assessment of post-traumatic stress disorder. International Clinical Psychopharmacology. 2001;16:279–284. - PubMed
-
- de Graaf R, Kessler RC, Fayyad J, ten Have M, Alonso J, Angermeyer M, Borges G, Demyttenaere K, Gasquet I, de Girolamo G, Haro JM, Jin R, Karam EG, Ormel J, Posada-Villa J. Adult Attention-Deficit/hyperactivity Disorder (ADHD) and the effects on performance in workers: Results from the WHO World Mental Health Survey Initiative. Occupational and Environmental Medicine in press. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical